Company intelligence / Profile preview

Sinovac Life Sciences

Beijing, Beijing, China

Ownership: Private
Employees: ~3000
Development stage: Other

Overview

Sinovac Life Sciences is a major global developer and manufacturer of vaccines for infectious diseases. It is most recognized for the development and mass production of CoronaVac, an inactivated COVID-19 vaccine that received WHO Emergency Use Listing. The company maintains a robust commercial portfolio including vaccines for Hepatitis A (Healive), Enterovirus 71 (Inlive), and various influenza strains.

Therapeutic areas: Infectious Diseases
Modalities: Vaccine
Industry: Biotech

Drug pipeline

5 assets

Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain

4 more assets in the full pipeline.

Request access →

Partnerships

Butantan InstituteBio FarmaSino BiopharmaceuticalVaxCell Bio

Beyond the preview

Go deeper on Sinovac Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinovac Life Sciences.

Explore the full profile